LATEST ONCOPRESCRIBE UPDATES
FDA Approves OPDIVO® with Chemotherapy for Previously Untreated Hodgkin Lymphoma
ASCO Recommendations on Circulating Tumor DNA Testing for Solid Tumors and Lymphoma
FDA Approves Imlunestrant in Combination with Abemaciclib for ER-positive, HER2-negative, ESR1-mutated Advanced Breast Cancer
Alcohol-Attributable Cancer Mortality in the United States Continues to Rise
Low-Dose Tamoxifen May Offer a Durable Endocrine Prevention Strategy After DCIS
Personalized Neoantigen Therapy Shows Durable Benefit in High-Risk Melanoma
OPTIMA Supports Genomic-Guided Chemotherapy Omission in Clinically High-Risk ER-Positive Early Breast Cancer
Subcutaneous Amivantamab Shows Promising Activity in Previously Treated HPV-Unrelated Advanced Head and Neck Cancer
NEW REGIMENS ADDED
VYLOY® with mFOLFOX 6 - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin), 5-FU and Leucovorin. Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveVYLOY® with CAPOX - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin) and XELODA® (Capecitabine). Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveENHERTU® - for Breast Cancer
Single Agent ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Ultralow Metastatic Breast CancerOPDIVO® and YERVOY® with Limited Course Chemotherapy - for Non Small Cell Lung Cancer
OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) with 2 cycles of TAXOL® (Paclitaxel) and PARAPLATIN®(Carboplatin) - for advanced NSCLCJAYPIRCA® - for Mantle Cell Lymphoma
JAYPIRCA® (Pirtobrutinib) for Mantle Cell Lymphoma
Curbside Consultation
Bottom Ad
Advertisement
Subscribe
